Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.61 |
| ▸ | CTSS | P25774 | 3/20 | 0.60 |
| ▸ | PPARA | Q07869 | 5/20 | 0.58 |
| ▸ | PPARG | P37231 | 4/20 | 0.58 |
| ▸ | ACE | P12821 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | PPARD | Q03181 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2856837 | 1.00 | CTSK (0.61) | CTSKCTSSPPARAPPARGACE | |
| SCHEMBL23177045 | 0.99 | CTSK (0.60) | CTSKCTSSPPARAPPARGACE | |
| SCHEMBL23176943 | 0.99 | CTSK (0.60) | CTSKCTSSPPARAPPARGACE | |
| SCHEMBL24814889 | 0.99 | CTSK (0.60) | CTSKCTSSPPARAPPARGACE | |
| SCHEMBL24814896 | 0.99 | CTSK (0.60) | CTSKCTSSPPARAPPARGACE | |
| SCHEMBL1374859 | 0.96 | CTSK (0.63) | CTSKCTSSPPARAPPARGACE | |
| SCHEMBL346311 | 0.96 | CTSK (0.63) | CTSKCTSSPPARAPPARGACE | |
| SCHEMBL2781406 | 0.96 | CTSK (0.63) | CTSKCTSSPPARAPPARGACE | |
| SCHEMBL181807 | 0.91 | CTSK (0.71) | CTSKCTSSPPARAPPARGACE | |
| SCHEMBL181775 | 0.91 | CTSK (0.71) | CTSKCTSSPPARAPPARGACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750162-B2 | Process for preparation of nonnatural amino acid and intermediate thereof | DAISO CO., LTD. (JP) | 2010-07-06 | — | — | US | disclosed |
| US-20070208180-A1 | Process for Preparation of Nonnatural Amino Acid and Intermediate Thereof | DAISO CO., LTD. (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1739077-A1 | PROCESS FOR PRODUCTION OF NONNATURAL AMINO ACIDS AND INTERMEDIATES THEREFOR | DAISO CO., LTD. (JP) | 2007-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208180-A1 | Process for Preparation of Nonnatural Amino Acid and Intermediate Thereof | BCAT1, BCAT2, AADAT | CTSK 3187/4885CTSS 2807/4885PPARA 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.